GMP IPO Watch
Striders Impex IPO: Playing for Keeps in the Global Toy Market
Mumbai-based Striders Impex launches its ₹36.29 crore NSE SME IPO on February 26, 2026. With an asset-light model that combines global brand licensing (Disney, etc.) and its own proprietary brands, the company is targeting massive expansion in India and the UAE. This blog covers the ₹71–₹72 price band, strong FY25 profits, and its strategic leap into international markets.
Live IPO tracking available
Check GMP movement, allotment details, subscription demand, and deeper IPO context for this company.
Use these shortcuts to keep exploring
The archive button opens all articles from this category. The IPO details button opens the live IPO page on your GMP site in a new tab.
1. The Business: More Than Just Toys
Founded in 2021, Striders Impex has quickly become a significant player in the toys and kids’ consumer merchandise segment. They don't just "sell" products; they handle the entire lifecycle—from design and licensing to sourcing and distribution.
The Asset-Light Secret: They don’t own factories. Instead, they design in Mumbai and outsource manufacturing to specialized vendors in India and China. This keeps costs low and flexibility high.
Global Powerhouses: They hold licenses for some of the world's biggest brands (like Disney) and distribute through top-tier retailers like Hamleys, Landmark Group, and Miniso.
Own Intellectual Property (IP): They aren't just relying on others. Brands like Pugs at Play, Furry Pals, and Minds at Play are their own creations, which typically offer higher profit margins.
2. Key IPO Dates & Price Details
The bidding opens tomorrow morning. Here is the schedule you need to save:
| Event / Detail | Information |
|---|---|
| IPO Opening Date | Thursday, February 26, 2026 (Tomorrow) |
| IPO Closing Date | Monday, March 2, 2026 |
| Price Band | ₹71 to ₹72 per share |
| Minimum Lot Size | 1,600 Shares |
| Min. Retail Investment | ₹2,30,400 (for 2 lots/3,200 shares) |
| Total Issue Size | ₹36.29 Crore |
| Listing Date | Friday, March 6, 2026 |
| Listing Exchange | NSE SME (NSE Emerge) |
3. Financial Health: Scaling Fast
The company has shown impressive growth in its short history:
Revenue Growth: Revenue jumped from ₹41.77 Cr (FY24) to ₹61.87 Cr (FY25).
Profitability (PAT): Net profit nearly doubled in a year, reaching ₹8.41 Cr in FY25.
Efficiency: They maintain a very high Return on Equity (ROE) of 55.8%, showing they are generating significant value from their capital.
Valuation: At the upper price band of ₹72, the P/E ratio is approximately 12.06x, which is considered quite reasonable for a high-growth consumer brand.
4. Grey Market Premium (GMP) & Sentiment
Current GMP: ₹0 (Flat) as of today.
Why the flat start? Grey market activity for SME IPOs often picks up once the subscription numbers start rolling in. Given the low P/E valuation, many analysts expect interest to build during the three-day bidding window.
5. Where is the Money Going?
The company is raising ₹32.62 Cr in fresh capital to:
Go International: Invest in a new wholly-owned subsidiary in the UAE to capture the Middle Eastern market.
Working Capital: To fund the inventory needed for their expanding pan-India distribution.
Debt Repayment: Paying off roughly ₹3 crore in loans to clean up the balance sheet.
6. Investor Analysis: Pros & Cons
Strengths:
Scalability: The asset-light model means they can double production without building a single factory.
Strategic Partners: Relationships with Disney and Hamleys act as a massive barrier for smaller competitors.
High Margins: Their owned-brand portfolio (IPs) helps them protect profits even if licensing costs rise.
Risks:
Licensing Dependence: If they lose a major license (like Disney), a chunk of revenue could disappear.
Import Risks: Sourcing from China makes them vulnerable to shipping delays and currency fluctuations.
SME Ticket Size: As an SME IPO, the minimum investment is ₹2.30 lakh, making it a play for serious retail investors and HNIs.
7. Conclusion
Striders Impex is a lean, mean, toy-selling machine. They have the right partnerships and a very high return on equity. While the lack of an initial "GMP pop" might make some cautious, the fundamentals—especially the 12x P/E valuation—suggest there is genuine value here for long-term investors.
